Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production - Level 2 revision

May 16, 2022

Guidance for Industry
May 2022

Today, FDA is announcing revisions to the 2006 guidance “Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production.” Specifically, this revision updates terminology for consistency with current FDA guidance, e.g., quality control unit is changed to quality unit, as well as clarifies concepts related to addressing outlier results, and practices related to the averaging of OOS results. This guidance provides FDA’s current thinking on how to evaluate OOS test results. For purposes of this guidance document, the term OOS results includes all test results that fall outside the specifications or acceptance criteria established in drug applications, drug master files, official compendia, or by the manufacturer. The term also applies to all in-process laboratory tests that are outside of established specifications.

Download the Final Guidance Document

Final Level 2    Revised Guidance

Interested in learning more? Contact us today to find out how we can help not only with your EMA/FDA submissions, but all of your global regulatory needs.




FDA North America

May 16, 2022

FDA Draft Guidance for Industry, Evaluation of Therapeutic Equivalence

FDA Draft Guidance July, 2022 As part of the FDA’s continued efforts to provide helpful information to regulated industry and the public, the agency has published a draft guidance for industry,...

Read More
FDA North America

May 16, 2022

FDA Issues Draft Guidance for Industry, Considerations for Rescinding Breakthrough Therapy Designation

Draft Guidance June 24, 2022 The U.S. Food and Drug Administration issued a draft guidance for industry titled Considerations for Rescinding Breakthrough Therapy Designation. This draft guidance...

Read More
ANDA FDA

May 16, 2022

FDA publishes two final guidances for industry: Orange Book Questions and Answers; Failure to Respond to an ANDA Complete Response Letter Within the Regulatory Timeframe

July 2022 As part of FDA’s continued efforts to improve transparency and provide helpful information to regulated industry and the public, the agency is issuing two final guidances for generic drug...

Read More